Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg and cytarabine in AML
NCT00037596Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2000
- Primary completion
- Apr 2003
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Started Aug 2000; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00037596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037596.